The third quarter of 2025 marked another milestone in China’s ongoing battle against cancer.The National Medical Products Administration (NMPA) granted approvals to several groundbreaking oncology drugs, giving new hope to patients and advancing China’s reputation as a global force in cancer innovation. As DengYue Medicine, a healthcare access and patient-support organization that...